Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 959 put options on the stock. This is an increase of approximately 1,179% compared to the average daily volume of 75 put options.

A number of large investors have recently modified their holdings of AUPH. Polar Capital LLP raised its stake in Aurinia Pharmaceuticals by 17.8% in the fourth quarter. Polar Capital LLP now owns 3,312,723 shares of the biotechnology company’s stock worth $22,593,000 after buying an additional 501,207 shares in the last quarter. FMR LLC raised its stake in Aurinia Pharmaceuticals by 7.9% in the fourth quarter. FMR LLC now owns 5,049,740 shares of the biotechnology company’s stock worth $34,439,000 after buying an additional 368,781 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Aurinia Pharmaceuticals by 47.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 388,811 shares of the biotechnology company’s stock worth $2,652,000 after buying an additional 124,940 shares in the last quarter. Franklin Resources Inc. raised its stake in Aurinia Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock worth $12,208,000 after buying an additional 105,300 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Aurinia Pharmaceuticals by 8,600.6% in the fourth quarter. Bank of America Corp DE now owns 30,713 shares of the biotechnology company’s stock worth $210,000 after buying an additional 30,360 shares in the last quarter. 24.30% of the stock is owned by institutional investors.

Several research firms have recently weighed in on AUPH. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Wednesday, January 9th. Raymond James lifted their price target on shares of Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the company an “outperform” rating in a research note on Wednesday. BidaskClub raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 28th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 price target (up previously from $18.00) on shares of Aurinia Pharmaceuticals in a research note on Tuesday. Finally, Royal Bank of Canada lifted their price target on shares of Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the company a “positive” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $13.75.

Shares of NASDAQ:AUPH opened at $6.83 on Thursday. The company has a market capitalization of $586.73 million, a P/E ratio of -8.99 and a beta of 1.38. Aurinia Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $7.85.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 45.80% and a negative net margin of 8,856.35%. On average, analysts forecast that Aurinia Pharmaceuticals will post -0.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/aurinia-pharmaceuticals-sees-unusually-high-options-volume-auph/2906064.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

See Also: What is Depreciation?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.